JNJ-95475939

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-95475939, covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) [Phase 2]